ZIDOVUDINE: CLINICAL EXPERIENCE IN SYMPTOMATIC HIV DISEASE NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


ZIDOVUDINE: CLINICAL EXPERIENCE IN SYMPTOMATIC HIV DISEASE

AIDS Clinical Review 1989. Volberding P and Jacobson MA, eds. New York, Marcel Dekker, p. 221-42, 1989.. Unique Identifier : AIDSLINE ICDB/90659415
Fischl MA; Univ. of Miami Sch. of Medicine, Miami, FL

Abstract: Zidovudine (AZT) is effective in the treatment of patients with advanced HIV disease, and it is likely that intervention with AZT early in the course of symptomatic HIV infection will prevent or delay progression to AIDS or AIDS-related illnesses and thereby change the natural history of HIV infection as currently recognized. Clinical experience with AZT is summarized under the following headings: clinical pharmacology, efficacy (survival, opportunistic infections, neurological disease, autoimmune thrombocytopenia, and other considerations), immunological monitoring, virological monitoring, adverse reactions (myositis, neurological toxicity, hematological toxicity, and hepatotoxicity), drug interactions, and prophylaxis for the prevention of HIV infection. (31 Refs)
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY AIDS Dementia Complex/DRUG THERAPY AIDS-Related Complex/DRUG THERAPY CD4-Positive T-Lymphocytes/DRUG EFFECTS Drug Interactions Human HIV/DRUG EFFECTS HIV Infections/*DRUG THERAPY/MORTALITY Leukocyte Count/DRUG EFFECTS Opportunistic Infections/DRUG THERAPY Survival Rate Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE MONOGRAPH REVIEW REVIEW, TUTORIALKWDacquiredimmunodeficiencysyndrome/drugtherapyaidsdementiacomplex/drugtherapyaids-relatedcomplex/drugtherapycd4-positivet-lymphocytes/drugeffectsdruginteractionshumanhiv/drugeffectshivinfections/KWDdrugtherapy/mortalityleukocytecount/drugeffectsopportunisticinfections/drugtherapysurvivalratezidovudine/adverseeffects/KWDtherapeuticusemonographreviewreview,tutorial
900430
M9040672

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .